Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Add'l Indications Recommended for Valtrex, Glivec
February 5, 2007
- MEXT to Strengthen Anticancer Efforts in FY2007
February 5, 2007
- Pfizer Japan, Astellas Announce Approval of Celecox
February 5, 2007
- Saiseikai Group to Initiate Study in Preparation for Joint Purchasing
February 5, 2007
- New Industry Vision to Focus on Environment for Drug Discovery: EAD Director
February 5, 2007
- MEDICAL DEVICE NEWS IN BRIEF
February 5, 2007
- Global Companies Move toClose Research Lab in Japan
February 5, 2007
- GE Healthcare Bio-Sciences Announces Tie-up with Effector Cell Institute
February 5, 2007
- Astellas, Kirin Tie Up for Fully Human Monoclonal Antibody
February 5, 2007
- Drug Evaluation Forum Begins -Drug Makers, PMDA, Academics to Exchange Opinions-
January 29, 2007
- Korosho to Announce Results of Survey on Use of Generics
January 29, 2007
- Chuikyo Approves NHI Price Listing for Alimta, Doxil
January 29, 2007
- Sysmex Develops in Vitro Diagnostic Technology for Cancers
January 29, 2007
- REGULATORY NEWS IN BRIEF
January 29, 2007
- Korosho Proposes "Medical Device MR System"
January 29, 2007
- Development of Amlodipine + Atorvastatin Combination Underway in Japan: Pfizer
January 29, 2007
- MEDICAL DEVICE NEWS IN BRIEF
January 29, 2007
- Ankhs Develops Drugs for Metastatic Cancer Using NR Ligands
January 29, 2007
- Retirement of Baby Boomers to Change Structure of Social Security System: Mr Kawasaki
January 29, 2007
- Kissei Announces Positive Results from PIII Trials of Silodosin in the US
January 29, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…